ProLung is delighted to be honored as the “Med Tech Company of the Year 2019” by Global Health & Pharma. Our ProLung team views external recognition as further validation of our mission to ‘make a difference in time’ for lung cancer patients who face under-prioritized and highly stigmatized disease that is still the leading cause of cancer deaths worldwide. We remain focused on making our patented ProLung Test™ the gold standard for determining the risk of malignancy in patients with indeterminate pulmonary nodules.

Read the award in Global Health & Pharma’s award supplement here:
https://www.ghp-news.com/2019-prolung

2019-03-08T00:00:00-06:00